Research Article| Volume 22, ISSUE 1, P40-52, January 2000

Tolerability and efficacy of nabumetone and naproxen in the treatment of rheumatoid arthritis

      This paper is only available as a PDF. To read, Please Download here.


      The purpose of this study was to compare the tolerability and efficacy of nabumetone and naproxen in the treatment of patients with rheumatoid arthritis (RA). The occurrence of gastrointestinal (GI) adverse events was compared.


      Nonsteroidal anti-inflammafory drugs (NSAIDs) have similar efficacy at equipotent doses, but the therapeutic response to various NSAIDs often differs in individual patients.


      This was a 3-month, randomized, double-blind, multicenter, parallel-group study conducted in adult patients with RA. The study had 2 phases: a 3-to 14-day washout period and a 12-week treatment period. During the treatment phase, the tolerability and efficacy of nabumetone 2000 mg/d were compared with those of naproxen 1000 mg/d. The change from baseline in efficacy variables, including global assessments, number of tender or swollen joints, and pain, was evaluated. The study was sized to provide an 80% power to detect a 15% difference in the percentage improvement on the physician's global assessment (α = 0.05). GI safety was assessed by monitoring the occurrence of clinically important adverse GI events.


      A total of 346 RA patients at 31 US rheumatology centers were randomly assigned to treatment (173 patients per group). The study population was predominantly white (87.0%) and female (70.5%), with a mean age of 54 years. Both treatments improved the signs and symptoms of RA, with no statistically significant differences between groups for any efficacy variables. No serious GI adverse events occurred with either NSAID. The most frequent treatment-related adverse events in both groups were predominantly GI in origin, as were those that resulted in withdrawal from the study. Diarrhea with lower abdominal pain was the most common adverse event in the nabumetone group; upper abdominal pain was the most common adverse event in the naproxen group. The only significant difference between the 2 groups was a higher incidence of diarrhea (P < 0.01) in patients receiving nabumetone.

      Key words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Clinical Therapeutics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Cush JJ
        • Jasin HE
        • Johnson R
        • Lipsky PE
        Relationship between clinical efficacy and laboratory correlates of inflammatory and immunologic activity in rheumatoid arthritis patients treated with nonsteroidal antiinflammatory drugs.
        Arthritis Rheum. 1990; 33: 623-633
        • Coles LS
        • Fries JF
        • Kraines RG
        • Roth SH
        From experiment to experience: Side effects of nonsteroidal anti-inflammatory drugs.
        Am J Med. 1983; 74: 820-828
        • Singh G
        • Triadafilopoulos G
        Epidemiology of NSAID induced gastrointestinal complications.
        J Rheumatol. 1999; 26: 18-24
        • Gabriel SE
        • Jaakkimainen L
        • Bombardier C
        Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs: A meta-analysis.
        Ann Intern Med. 1991; 115: 787-796
        • Simon LS
        • Hatoum HT
        • Bittman RM
        • et al.
        Risk factors for serious nonsteroidalinduced gastrointestinal complications: Regression analysis of the MUCOSA trial.
        Fam Med. 1996; 28: 204-210
        • Griffin MR
        Epidemiology of nonsteroidal anti-inflammatory drug-associated gastrointestinal injury.
        Am J Med. 1998; 104: 23S-29S
        • Scheiman JM
        NSAIDs: Gastrointestinal injury and cytoprotection.
        Gastroenterol din North Am. 1996; 25: 279-298
        • Garcia Rodriguez LA
        • Jick H
        Risk of upper gastrointestinal bleeding and perforation associated with individual non-steroidal anti-inflammatory drugs.
        Lancet. 1994; 343: 769-772
        • Singh G
        • Terry R
        • Ramey DR
        • et al.
        Comparative GI toxicity of NSAIDs.
        Arthritis Rheum. 1997; 40 (Abstract): S115
        • Henry D
        • Lim LL
        • Garcia Rodriguez LA
        • et al.
        Variability in risk of gastrointestinal complications with individual non-steroidal anti-inflammatory drugs: Results of a collaborative meta-analysis.
        Br Med J. 1996; 312: 1563-1566
        • MacDonald TM
        • Morant SV
        • Robinson GC
        • et al.
        Association of upper gastrointestinal toxicity of non-steroidal anti-inflammatory drugs with continued exposure: Cohort study.
        Br Med J. 1997; 315: 1333-1337
        • Lipani JA
        • Poland M
        Clinical update of the relative safety of nabumetone in long-term clinical trials.
        Inflammopharmacology. 1995; 3: 351-361
        • Porro GB
        • Montrone F
        • Petrillo M
        • et al.
        Gastroduodenal tolerability of nabumetone versus naproxen in the treatment of rheumatic patients.
        Am J Gastroenterol. 1995; 90: 1485-1488
        • Roth SH
        • Bennett R
        • Caldron P
        • et al.
        A long-term endoscopic evaluation of patients with arthritis treated with nabumetone vs. naproxen.
        J Rheumatol. 1994; 21: 1118-1123
        • Lister BJ
        • Poland M
        • DeLapp R
        Efficacy of nabumetone versus diclofenac, naproxen, ibuprofen, and piroxicam in osteoarthritis and rheumatoid arthritis.
        Am J Med. 1993; 95: 2S-9S
        • Eversmeyer W
        • Poland M
        • DeLapp RE
        • Jensen CP
        Safety experience with nabumetone versus diclofenac, naproxen, ibuprofen, and piroxicam in osteoarthritis and rheumatoid arthritis.
        Am J Med. 1993; 95: 10S-18S
        • Arnett FC
        • Edworthy SM
        • Block DA
        • et al.
        The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis.
        Arthritis Rheum. 1988; 31: 315-324
        • Steinbrocker O
        • Traeger CH
        • Batterman RC
        Therapeutic criteria in rheumatoid arthritis.
        JAMA. 1949; 140: 659-662
        • Hochberg MC
        • Chkang W
        • Dwash I
        • et al.
        The American College of Rheumatology 1991 revised criteria for the classification of global functional status in RA.
        Arthritis Rheum. 1992; 35: 498-502
        • Meenan RF
        • Mason JH
        • Anderson JJ
        • et al.
        AIMS2. The content and properties of a revised and expanded Arthritis Impact Measurement Scales Health Status questionnaire.
        Arthritis Rheum. 1992; 35: 1-10
        • Mason JH
        • Anderson JJ
        • Meenan RF
        • et al.
        The Rapid Assessment of Disease Activity in Rheumatology (RADAR) questionnaire. Validity and sensitivity to change of a patient self-report measure of joint count and clinical status.
        Arthritis Rheum. 1992; 35: 156-162
        • Pincus T
        • Griffin M
        Gastrointestinal disease associated with nonsteroidal antiinflammatory drugs: New insights from observational studies and functional status questionnaires.
        Am J Med. 1991; 90: 209-212
        • Silverstein FE
        • Graham DY
        • Senior JR
        • et al.
        Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. A randomized, double-blind, placebo-controlled trial.
        Ann Intern Med. 1995; 123: 241-249
        • Fleischmann RM
        A controlled study comparing the effects of nabumetone, ibuprofen and ibuprofen plus misoprostol on the upper gastrointestinal tract mucosa.
        Arch Intern Med. 1993; 153: 2565-2571
        • Bernhard GC
        • Appelrouth DJ
        • Bankhurst AD
        • et al.
        Long-term treatment of rheumatoid arthritis comparing nabumetone with aspirin.
        Am J Med. 1987; 83: 44-49
        • Emery P
        • Clarke A
        • Williams P
        • et al.
        Nabumetone compared with naproxen in the treatment of rheumatoid arthritis: A multicenter, double-blind, randomized, parallel group trial in hospital outpatients.
        J Rheumatol. 1992; 19: 41-47